Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2020-11-16 Interim / Quarterly Rep…
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements (unaudited)' for the three- and six-month periods ended September 30, 2020. It contains detailed financial statements including Statements of Financial Position, Income, Changes in Shareholders' Equity, and Cash Flows, along with notes explaining accounting policies and the impact of COVID-19. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of interim financial statements and the reference to IAS 34 (Interim Financial Reporting) confirms this is a quarterly or half-year financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2020-11-16 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for the three- and six-month periods ended September 30, 2020. It contains detailed financial performance discussion, including revenue, EBITDA, operating income, liquidity, and other financial metrics for these interim periods. The document references unaudited condensed interim consolidated financial statements prepared under IFRS, which aligns with typical content of an Interim / Quarterly Report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2020-11-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Medexus Pharmaceuticals has reached 50% enrollment in a Phase 4 clinical trial for IXINITY, targeting label expansion for pediatric hemophilia B patients. It discusses clinical trial progress, market potential, and forward-looking statements. There are no financial statements, regulatory certifications, voting results, or management changes. The content is an update on clinical trial progress and business development rather than a formal financial or regulatory filing. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing or announcement of a report publication. The document fits best as a general regulatory announcement or business update, which falls under Regulatory Filings (RNS).
2020-11-16 English
News release - English.pdf
Call Transcript Classification · 85% confidence The document is a press release announcing a scheduled conference call to discuss the company's financial results for the fiscal 2021 second quarter. It mentions the date and time of the call, how to access it, and that the financial statements and MD&A will be filed separately. The document does not contain actual financial data or detailed financial analysis, but rather serves as an announcement for the upcoming earnings call. According to the classification rules, such announcements of conference calls are classified as Call Transcript (CT) if they contain the transcript, but this document is only a scheduling announcement, not the transcript itself. It is not a report publication announcement (RPA) because it is about a call, not a report release. The best fit is Call Transcript (CT) category as it relates to the earnings call event, even though it is a scheduling announcement, since no other category fits better and it is directly related to the earnings call event.
2020-11-09 English
News release - English.pdf
Regulatory Filings
2020-10-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a short announcement about Medexus Pharmaceuticals presenting at the MicroCap Rodeo Best Ideas Bowl conference. It includes details about the presentation date, time, and how to access the webcast. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory content. The document is under 5,000 characters and serves as an announcement of an event rather than a report or transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2020-10-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.